Spirapril: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Protected "Spirapril": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
No edit summary
 
(3 intermediate revisions by 2 users not shown)
Line 20: Line 20:
{{CMG}}
{{CMG}}


{{Editor Join}}
==Overview==
'''Spirapril hydrochloride''' (Renormax) is an [[ACE inhibitor]] [[antihypertensive]] drug used to treat [[hypertension]].
It belongs to dicarboxy group of ace inhibitor.


Like many ACE inhibitors, this is a [[prodrug]] which is converted to the active metabolite [[spiraprilat]] following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes which may allow for greater use in patients with renal impairment.<ref>{{cite journal | author = Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G | title = Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension. | journal = Scand J Urol Nephrol | volume = 33 | issue = 1 | pages = 57&ndash;62 | year = 1999 | pmid = 10100366 | doi = 10.1080/003655999750016294}}</ref>
However data on its effect upon the [[renal function]] is conflicting.<!--
  --><ref>{{cite journal | author = Noble S, Sorkin E | title = Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. | journal = Drugs | volume = 49 | issue = 5 | pages = 750&ndash;66 | year = 1995 | pmid = 7601014 | doi=10.2165/00003495-199549050-00008}}</ref>


It is produced synthetically by combining the following two pharmaceutical intermediates:


(''S'')-1,4-Dithia-7-azaspiro(4,4)-nonane-8-carboxylic acid hydrobromide
CAS 75776-79-3


==Overview==
and
'''Spirapril hydrochloride''' (Renormax&reg;) is an [[ACE inhibitor]] [[antihypertensive]] drug used to treat [[hypertension]].


Like many ACE inhibitors, this is a [[prodrug]] which is converted to the active metabolite spiraprilat following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes which may allow for greater use in patients with renal impairment.<!--
N-[1-(''S'')-ethoxycarbonyl-3-phenylpropyl)-L-Alanine (ECPPA) [http://www.mainpluschem.com/Spirapril/spirapril.html]
  --><ref>{{cite journal | author = Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G | title = Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension. | journal = Scand J Urol Nephrol | volume = 33 | issue = 1 | pages = 57-62 | year = 1999 | id = PMID 10100366}}</ref>
However data on its effect upon the [[renal function]] is conflicting.<!--
  --><ref>{{cite journal | author = Noble S, Sorkin E | title = Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. | journal = Drugs | volume = 49 | issue = 5 | pages = 750-66 | year = 1995 | id = PMID 7601014}}</ref>


==Footnotes==
==Footnotes==
<references/>
{{Reflist|2}}
 
{{ACE inhibitors}}


[[Category:ACE inhibitors]]
[[Category:ACE inhibitors]]
[[Category:prodrugs]]
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]
[[Category:Drug]]
 
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 20:51, 23 July 2014

Spirapril
Clinical data
Pregnancy
category
  • D
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability50%
Metabolismconverted to spiraprilat
Elimination half-life30 to 35 hours
ExcretionHepatic and renal
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H30N2O5S2
Molar mass466.616 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Spirapril hydrochloride (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension. It belongs to dicarboxy group of ace inhibitor.

Like many ACE inhibitors, this is a prodrug which is converted to the active metabolite spiraprilat following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes which may allow for greater use in patients with renal impairment.[1] However data on its effect upon the renal function is conflicting.[2]

It is produced synthetically by combining the following two pharmaceutical intermediates:

(S)-1,4-Dithia-7-azaspiro(4,4)-nonane-8-carboxylic acid hydrobromide CAS 75776-79-3

and

N-[1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-Alanine (ECPPA) [2]

Footnotes

  1. ↑ Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G (1999). "Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension". Scand J Urol Nephrol. 33 (1): 57&ndash, 62. doi:10.1080/003655999750016294. PMID 10100366.
  2. ↑ Noble S, Sorkin E (1995). "Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension". Drugs. 49 (5): 750&ndash, 66. doi:10.2165/00003495-199549050-00008. PMID 7601014.
Retrieved from "https://www.wikidoc.org/index.php?title=Spirapril&oldid=999941"